Barinthus Biotherapeutics (NASDAQ:BRNS) versus Candel Therapeutics (NASDAQ:CADL) Head-To-Head Contrast

Candel Therapeutics (NASDAQ:CADL) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Profitability

This table compares Candel Therapeutics and Barinthus Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-29.24%	-22.63%
Barinthus Biotherapeutics	N/A	-70.13%	-56.09%

Insider & Institutional Ownership

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 16.6% of Candel Therapeutics shares are held by insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Candel Therapeutics and Barinthus Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	$120,000.00	2,152.54	-$55.18 million	($0.57)	-8.25
Barinthus Biotherapeutics	$14.97 million	2.06	-$61.07 million	($1.88)	-0.40

Candel Therapeutics has higher earnings, but lower revenue than Barinthus Biotherapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Candel Therapeutics has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.67, suggesting that its share price is 167% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Candel Therapeutics and Barinthus Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1	1	4	2	2.88
Barinthus Biotherapeutics	1	0	2	0	2.33

Candel Therapeutics currently has a consensus price target of $18.33, indicating a potential upside of 289.66%. Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 429.80%. Given Barinthus Biotherapeutics’ higher probable upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Candel Therapeutics.

Summary

Candel Therapeutics beats Barinthus Biotherapeutics on 9 of the 14 factors compared between the two stocks.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.